Literature DB >> 16877060

Human papillomaviruses and cervical cancer.

Daniel DiMaio1, John B Liao.   

Abstract

Carcinoma of the uterine cervix, a leading cause of cancer death in women worldwide, is initiated by infection with high-risk types of human papillomaviruses (HPVs). This review summarizes laboratory studies over the past 20 years that have elucidated the major features of the HPV life cycle, identified the functions of the viral proteins, and clarified the consequences of HPV infection for their host cells. This information has allowed the development of various strategies to prevent or treat infections, including prophylactic vaccination with virus-like particles, therapeutic vaccination against viral proteins expressed in cancer cells, and antiviral approaches to inhibit virus replication, spread, or pathogenesis. These strategies have the potential to cause a dramatic reduction in the incidence of cervical carcinoma and serve as the prototype for comprehensive efforts to combat virus-induced tumors.

Entities:  

Mesh:

Year:  2006        PMID: 16877060     DOI: 10.1016/S0065-3527(06)66003-X

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  21 in total

1.  HPV E6 proteins target Ubc9, the SUMO conjugating enzyme.

Authors:  Phillip R Heaton; Adeline F Deyrieux; Xue-Lin Bian; Van G Wilson
Journal:  Virus Res       Date:  2011-04-12       Impact factor: 3.303

2.  Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets.

Authors:  Yingfei Ma; Ramana Madupu; Ulas Karaoz; Carlos W Nossa; Liying Yang; Shibu Yooseph; Patrick S Yachimski; Eoin L Brodie; Karen E Nelson; Zhiheng Pei
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

3.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

Review 4.  Regulation of human papillomavirus gene expression by splicing and polyadenylation.

Authors:  Cecilia Johansson; Stefan Schwartz
Journal:  Nat Rev Microbiol       Date:  2013-03-11       Impact factor: 60.633

Review 5.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

6.  Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin.

Authors:  Nicole Spardy; Kathryn Covella; Elliot Cha; Elizabeth E Hoskins; Susanne I Wells; Anette Duensing; Stefan Duensing
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells.

Authors:  Nicole Spardy; Anette Duensing; Domonique Charles; Nathan Haines; Tomomi Nakahara; Paul F Lambert; Stefan Duensing
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

8.  The DNA binding domain of a papillomavirus E2 protein programs a chimeric nuclease to cleave integrated human papillomavirus DNA in HeLa cervical carcinoma cells.

Authors:  Stacy M Horner; Daniel DiMaio
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

9.  Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.

Authors:  John B Liao; Jean Publicover; John K Rose; Daniel DiMaio
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

Review 10.  The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.

Authors:  Maciej Lazarczyk; Patricia Cassonnet; Christian Pons; Yves Jacob; Michel Favre
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.